DelveInsight’s, “Type 4 Cyclic Nucleotide Phosphodiesterase Inhibitors - Pipeline Insight, 2022,” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Type 4 Cyclic Nucleotide Phosphodiesterase Inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Type 4 Cyclic Nucleotide Phosphodiesterase Inhibitors: Overview
Cyclic nucleotide phosphodiesterases (PDEs) catalyze the hydrolytic destruction of the intracellular second messengers, cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP), to produce 5’-AMP and 5’-GMP, respectively. Type 4 cyclic nucleotide phosphodiesterases (PDE4) are a family of low km 3',5'-cyclic adenosine monophosphate (cAMP)-specific phosphodiesterases including at least 20 isozymes encoded by four genes (PDE4A, PDE4B, PDE4C, and PDE4D) in mammals. Because PDE4 isoforms exhibit widespread tissue distribution, perhaps more than any other PDE family, inhibition of PDE4 enzymes alters cAMP-signaling in many cells. The development of PDE4 inhibitors with improved therapeutic indexes has been a major focus of pharmaceutical research for the treatment of chronic inflammatory diseases.
The companies and academics are working to assess challenges and seek opportunities that could influence Type 4 Cyclic Nucleotide Phosphodiesterase Inhibitors R&D. The therapies under development are focused on novel approaches for Type 4 Cyclic Nucleotide Phosphodiesterase Inhibitors.
This segment of the Type 4 Cyclic Nucleotide Phosphodiesterase Inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Type 4 Cyclic Nucleotide Phosphodiesterase Inhibitors Emerging Drugs
Ensifentrine : Verona Pharma
Ensifentrine is an inhaled, first-in-class dual inhibitor of phosphodiesterase 3 (PDE3) and 4 (PDE4). The drug is in Phase III clinical studies for the treatment of chronic obstructive pulmonary disease and in Phase II developmental studies for asthma and cystic fibrosis treatment. In April 2021, Verona Pharma has reported positive data from a pilot study evaluating a pressurised metered-dose inhaler (pMDI) formulation of ensifentrine to treat Covid-19.
Difamilast: Otsuka Pharmaceutical
Difamilast is an investigational non-steroidal topical anti-inflammatory PDE4 inhibitor. The drug is in development for the treatment of mild to moderate atopic dermatitis. Medimetriks has sole exclusive U.S rights to develop and commercialize MM36 (difamilast). In September 2020, Otsuka Pharmaceutical announced that an application has been submitted to the Pharmaceuticals and Medical Devices Agency in Japan to seek manufacturing and marketing approval for difamilast (OPA-15406) in patients with atopic dermatitis.
Further product details are provided in the report……..
This segment of the report provides insights about the different Type 4 Cyclic Nucleotide Phosphodiesterase Inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
There are approx. 20+ key companies which are developing the Type 4 Cyclic Nucleotide Phosphodiesterase Inhibitors. The companies which have their Type 4 Cyclic Nucleotide Phosphodiesterase Inhibitors drug candidates in the most advanced stage, i.e. Preregistration include, Otsuka Pharmaceutical.
DelveInsight’s report covers around 20+ products under different phases of clinical development like
Type 4 Cyclic Nucleotide Phosphodiesterase Inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Products have been categorized under various Molecule types such as
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Type 4 Cyclic Nucleotide Phosphodiesterase Inhibitors therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Type 4 Cyclic Nucleotide Phosphodiesterase Inhibitors drugs.
Current Scenario and Emerging Therapies:
Introduction
Executive Summary
Type 4 Cyclic Nucleotide Phosphodiesterase Inhibitors: Overview
Pipeline Therapeutics
Therapeutic Assessment
Type 4 Cyclic Nucleotide Phosphodiesterase Inhibitors – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Type 4 Cyclic Nucleotide Phosphodiesterase Inhibitors Collaboration Deals
Late Stage Products (Phase III)
Ensifentrine: Verona Pharma
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Tanimilast: Chiesi Farmaceutici
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Drug name: Company name
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
BTX-2640: BioTheryX
Drug profiles in the detailed report…..
Inactive Products
Type 4 Cyclic Nucleotide Phosphodiesterase Inhibitors Key Companies
Type 4 Cyclic Nucleotide Phosphodiesterase Inhibitors Key Products
Type 4 Cyclic Nucleotide Phosphodiesterase Inhibitors- Unmet Needs
Type 4 Cyclic Nucleotide Phosphodiesterase Inhibitors- Market Drivers and Barriers
Type 4 Cyclic Nucleotide Phosphodiesterase Inhibitors- Future Perspectives and Conclusion
Type 4 Cyclic Nucleotide Phosphodiesterase Inhibitors Analyst Views
Type 4 Cyclic Nucleotide Phosphodiesterase Inhibitors Key Companies
Appendix
List of Table
Table 1: Total Products for Type 4 Cyclic Nucleotide Phosphodiesterase Inhibitors
Table 2: Late Stage Products
Table 3: Mid Stage Products
Table 4: Early Stage Products
Table 5: Pre-clinical & Discovery Stage Products
Table 6: Assessment by Product Type
Table 7: Assessment by Stage and Product Type
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type
Table 12: Inactive Products
List of Figures
Figure 1: Total Products for Type 4 Cyclic Nucleotide Phosphodiesterase Inhibitors
Figure 2: Late Stage Products
Figure 3: Mid Stage Products
Figure 4: Early Stage Products
Figure 5: Preclinical and Discovery Stage Products
Figure 6: Assessment by Product Type
Figure 7: Assessment by Stage and Product Type
Figure 8: Assessment by Route of Administration
Figure 9: Assessment by Stage and Route of Administration
Figure 10: Assessment by Molecule Type
Figure 11: Assessment by Stage and Molecule Type
Figure 12: Inactive Products
• Verona Pharma
• MediciNova
• Innovation Pharmaceuticals
• Otsuka Pharmaceutical
• Chiesi Farmaceutici
• BioTheryX
• AnnJi Pharmaceutical
• UNION Therapeutics
• MediciNova
• Amgen
• Arcutis Biotherapeutics
